These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11258198)

  • 1. Pharmacogenetics of human androgens and prostatic diseases.
    Novelli G; Margiotti K; Sangiuolo F; Reichardt JK
    Pharmacogenomics; 2001 Feb; 2(1):65-72. PubMed ID: 11258198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of human androgens and prostate cancer--an update.
    Novelli G; Margiotti K; Chiocca AM; Spera E; Micali F; Reichardt JK
    Pharmacogenomics; 2004 Apr; 5(3):283-94. PubMed ID: 15102543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia.
    Koivisto PA; Schleutker J; Helin H; Ehren-van Eekelen C; Kallioniemi OP; Trapman J
    Clin Cancer Res; 1999 Nov; 5(11):3578-82. PubMed ID: 10589774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study.
    Balistreri CR; Caruso C; Carruba G; Miceli V; Candore G
    OMICS; 2011 Jun; 15(6):369-74. PubMed ID: 21348640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 7. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
    Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
    Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
    Akalu A; Dlmajian DA; Highshaw RA; Nichols PW; Reichardt JK
    J Urol; 1999 Apr; 161(4):1355-8. PubMed ID: 10081907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
    Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
    Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
    Makridakis N; Reichardt JK
    J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
    Luo J; Dunn TA; Ewing CM; Walsh PC; Isaacs WB
    Prostate; 2003 Oct; 57(2):134-9. PubMed ID: 12949937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
    Hsieh JT; Chen SC; Yu HJ; Chang HC
    Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
    Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
    Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
    Makridakis N; Ross RK; Pike MC; Chang L; Stanczyk FZ; Kolonel LN; Shi CY; Yu MC; Henderson BE; Reichardt JK
    Cancer Res; 1997 Mar; 57(6):1020-2. PubMed ID: 9067262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate.
    Azzouzi AR; Cochand-Priollet B; Mangin P; Fournier G; Berthon P; Latil A; Cussenot O
    Eur J Endocrinol; 2002 Oct; 147(4):479-84. PubMed ID: 12370109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
    Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
    Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
    Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
    Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.